Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Malignant Neoplasms of Female Genital Organs
Interventions
DRUG

Fulvestrant

"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."

DRUG

Abemaciclib

"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER